All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A1c, systolic blood pressure, and low-density lipoprotein cholesterol levels

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Chiang, Hou Hsien ^a   Tseng, Fen Yu ^b   Wang, Chih Yuan ^b   Chen, Chi Ling ^c   Chen, Yi Chun ^c   See, Ting Ting ^a   Chen, Hua Fen ^a  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TAIWAN; AGED; BLOOD; BLOOD PRESSURE; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HEALTH SURVEY; MIDDLE AGED;

AGED; BLOOD PRESSURE; CAUSE OF DEATH; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PUBLIC HEALTH SURVEILLANCE; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84908573923     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109501     Document Type: Article

References (46)

1. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
3. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. (2008) Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559.
4. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al.; ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572.
5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al.; VADT Investigators (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139.
6. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, et al.; ACCORD Study Group (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364: 818-828.
7. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, et al. (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375: 481-489.
8. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ (2011) Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care 34: 1329-1336.
9. Colayco DC, Niu F, McCombs JS, Cheetham TC (2011) A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 34: 77-83.
10. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, et al. (2010) New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 268: 471-482.
11. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, et al.; CHARM Program Investigators (2008) The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 168: 1699-1704.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572.
13. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12 yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444.
14. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321: 412-419.
15. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713.
16. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, et al.; HOT Study Group (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755-1762.
17. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321: 412-419.
18. American Diabetes Association (2013) Standards of medical care in diabetes - 2013. Diabetes Care 36: S11-S66.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572.
20. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. (2010) ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575-1585.
21. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. (2004) CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364: 685-696.
22. Pyorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, et al. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620.
23. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, et al. (1998) the Care Investigators: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98: 2513-2519.
24. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
25. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, et al. (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28: 1151-1157.
26. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. (2008) Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117-125.
27. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, et al. (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29: 1220-1226.
28. Tseng CH (2004) Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 27: 1605-1609.
29. Bureau of National Health Insurance website. [http://www.nhi.gov.tw/resource/bulletin/421-0890036465-19.doc] Accessed April 1, 2013.
30. Epstein AE, Abraham WT, Bianco NR, Kern KB, Mirro M, et al. (2013) Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol 62: 2000-2007.
31. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, et al. (2013) Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 309: 355-363.
32. Kennedy BS, Kasl SV, Brass LM, Vaccarino V (2002) Trends in hospitalized stroke for blacks and whites in the United States, 1980-1999. Neuroepidemiology 21: 131-141.
33. Chen HF, Chen P, Li CY (2011) Risk of malignant neoplasm of the pancreas in relation to diabetes: a population-based study in Taiwan. Diabetes Care 34: 1177-1179.
34. Wu MY, Hsu YH, Su CL, Lin YF, Lin HW (2012) Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis 60: 548-552.
35. Li HY, Jiang YD, Chang CH, Chung CH, Lin BJ, et al. (2012) Mortality trends in patients with diabetes in Taiwan: a nationwide survey in 2000-2009. J Formos Med Assoc 111: 645-650.
36. Hayes AJ, Leal J, Kelman CW, Clarke PM (2011) Risk equations to predict life expectancy of people with Type 2 diabetes mellitus following major complications: a study from Western Australia. Diabet Med 28: 428-435.
37. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, et al.; ADVANCE Collaborative Group (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363: 1410-1418.
38. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, et al. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765-1772.
39. Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, et al. (2010) Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 33: 1591-1597.
40. Cooper-DeHoff RM, Gong Y, Handberg EM, Handberg EM, Bavry AA, et al. (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304: 61-68.
41. Vamos EP, Harris M, Millett C, Pape UJ, Khunti K, et al. (2012) Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ 345: e5567.
42. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, et al. (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507-520.
43. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
44. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, et al.; A to Z Investigators (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292: 1307-1316.
45. Tikhonoff V, Casiglia E, Mazza A, Scarpa R, Thijs L, et al. (2005) Low-density lipoprotein cholesterol and mortality in older people. J Am Geriatr Soc 53: 2159-2164.
46. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, et al. (2005) Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 53: 219-226.